the relatively low seizure-free rates, rarely being higher than 50% [5] . Besides difficulties in exact localization of the epileptogenic focus, one of the greatest challenges is encountered when the epileptogenic lesion involves eloquent cortex areas. In such cases surgery may be performed but the risk for permanent neurological deficit (up to 25% [6] ) should be taken into consideration.
Stereotactic radiosurgery (SRS) or hypofractionated/fractionated stereotactic radiotherapy (hf/fSRT) may represent an alternative and safe treatment option for epileptogenic lesions involving highly eloquent cortex areas like motor cortex, primary visual cortex or insular cortex. Beside their noninvasive nature, both SRS and SRT can be stereotactically applied, thus making them a preferred option for lesions nearby or within eloquent cortex areas. The idea of attempting to eliminate epileptogenic foci by stereotactic means is not novel; it has been pursued since the 1970s [7] and recently a number of different ablation techniques have been used in the treatment of pharmacoresistant epilepsy [8, 9] . Although the initial results of stereotactic treatment were heterogeneous and not completely convincing, the better understanding of seizure generation and the concept of the epileptogenic zone have lead to a more successful usage of these modalities [10] , so that radiosurgery for e.g. epileptogenic hamartomas and for MTLE have emerged as valuable alternative treatment options [11] [12] [13] .
Modern radiosurgical techniques include, in addition to the classical SRS (single-stage high-precision radiation), the so-called hypofractionated or fractionated stereotactic high precision radiotherapy (SRT). Fractionated SRT is an increasingly used method of radiotherapy treatment for many benign and malignant brain lesions and has been already carried out for treatment of drug-resistant focal epilepsy, but conclusive evidence is still lacking [14] [15] [16] . Although the use of SRS and SRT has been mainly used to treat MTLE or hypothalamic hamartomas, there are other highly epileptogenic lesions, which could benefit from these treatment modalities as well. Such lesions comprise focal cortical dysplasia (FCD), which are characterized by an erroneous cortical architecture and abnormal arrangement of the nerve cells. Currently, FCDs are classified in three types according to neuropathological findings with different electroclinical course, magnetic resonance imaging (MRI) findings and postsurgical outcome [17] . FCD type IIb is the most commonly diagnosed group showing a characteristic tail between the cortex and the lateral ventricles. A complete resection of the cortical malformation is the most important prognostic factor for postoperative seizure freedom. However, removal of the tail is not relevant for outcome, but to spare it reduces the potential surgical risks [18] . The complete microsurgical resection of FCD can be difficult especially in deep-seated and/or eloquent located FCD. In these challenging cases, the complete resection could only be performed with subsequent significant and permanent neurological deficits.
In summary, stereotactic irradiation has already been performed for treatment of pharmacoresistant epilepsies and showed some promising results with an acceptable and less overall side effect profile than microsurgery, but this form of therapy has only rarely been studied in FCD. We postulated that focal pharmacoresistant epilepsies due to FCD are also well treatable with stereotactic irradiation. Here, we investigated the safety and efficacy of a low-dose high-precision irradiation in patients with pharmacoresistant focal epilepsies mainly due to FCD. Our results indicate that low dose irradiation of circumscribed epileptogenic lesions may lead to lasting neuromodulatory effects with an acceptable seizure control, suggesting that low-dose high precision irradiation may be a feasible and efficacious alternative treatment option in pharmacoresistant focal epilepsies arising from highly eloquent areas with possibly fewer side effects as compared to standard microsurgical resection. From January 2013 until December 2014 a total of 10 patients were prospectively identified with drug-resistant focal epilepsy which met the eligibility criteria, six patients agreed and were included in the study. All patients presented with an eloquent localized epileptogenic lesion mainly suggestive for FCD. There were four male and two female patients. Further patients' characteristics are presented in Table 1 .
Methods

Cohort description and epilepsy diagnostic
All patients underwent presurgical evaluation using a standard protocol [19] . For each patient, 3.0 Tesla MRI, ictal and interictal scalp video-EEG and neuropsychological testing were routinely performed. If necessary additional investigations including ictal and interictal SPECT/PET imaging and MRI-postprocessing methods (MAP, Morphometric Analysis Program) were performed.
In four patients a second-stage invasive diagnostic was needed to confirm the putative epileptogenic lesions, which included the implantation of depth electrodes (sEEG, stereo-EEG) in three and placement of subdural electrodes in one patient. Additional stereotactic biopsy was performed in 2 patients (Tables 2 and 3) . Every patient was evaluated by at least one experienced epileptologist. All patients underwent video-EEG monitoring at the Department of Epileptology for seizure recordings. Antiepileptic drugs were usually tapered off to facilitate seizure onset. The correct localization of the depth electrodes was confirmed with MRI [20] .
After the presurgical evaluation and confirmation of the epileptogenic focus a surgical intervention was discussed with all patients. Due to eloquent localization of the epileptogenic lesions, consequently leading to a high risk for permanent neurological deficit, all patients were offered a stereotactic irradiation as an alternative treatment option after interdisciplinary discussion. For all patients informed consent was obtained according to the Declaration of Helsinki and the therapy was offered as an individualized treatment.
Treatment protocol
The Clinical Target Volume (CTV) was defined as the visible epileptogenic lesion using magnetic resonance imaging (MRI) alone or as the zone suggestive for FCD combining MRI, Morphometric Analysis Program (MAP) and active electrode contacts of the sEEG. In FCD Type IIb the typical so-called tail was not included, which also corresponds to an alternative microsurgical procedure. For radiosurgery the Planning Target Volume (PTV) was identical with the CTV without any additional safety margin. In case of fractionated stereotactic irradiation, a safety margin of 1 mm was placed around the CTV. The decision whether a one-stage or fractionated stereotactic irradiation was appropriate depended mainly on the volume and the radiosensivity of the organs at risk (OARs):
High-risk and/or PTV > 4 cc > fractionated stereotactic irradiation with 12 Â 3 Gy. Low-risk and/or PTV 4 cc > single session radiosurgery with a radiobiological equivalent marginal dose of 13 Gy and 15 Gy maximal dose (Fig. 1a and b) .
Patient immobilization, treatment planning, geometrical accuracy of and clinical experiences with the Novalis 1 system used here have already been reported [21] .
Follow-up and seizure outcome
After SRS/SRT, all patients were followed at 6 and 12 months during the first year, and at intervals of 12 months thereafter. Regular follow-up studies included clinical examination, brain MRI, and evaluation by an experienced epileptologist.
Seizure outcome was evaluated according to the ILAE classification [22] . Patients displaying ILAE class 1, 2 or 3 at the last available outcome were classified as having favorable outcome, corresponding to combined Engel I and II.
Results
Patients
From May 2013 until December 2014 six patients were treated. Age ranged from 20 to 42 years (mean, 28,3 years). Sex relation, target volumes, invasive diagnostics, treatment modalities (SRS/ SRT) and follow-up are presented in Tables 1-3.
Treatment modalities, target volumes and lesions localization
Four patients were treated with SRS (low risk and/or <4 ccm) and two patients were treated with fractionated SRT (high risk and/or !4 ccm) using the Novalis 1 system. The mean Clinical Target Volume (CTV) for SRS was 1.74 cc, whereas the mean CTV for hfSRT was 3.84 cc. In one case (Pat. No. 6) the CTV was 4.26 cc, but in this case SRS was preferred because the configuration of the lesion and the relation to the OAR (here the pyramidal tract) allowed a safe modeling of the critical isodose lines (Fig. 1a) . In another case (Pat. No. 1, Fig. 1b ) the CTV was 3.36 cc, but hfSRT was preferred because of a direct involvement of the OAR (here the fornix).
All epileptogenic lesions were localized in eloquent cortex areas. This included three lesions in the precentral gyrus, one lesion in the insular cortex, one lesion in the primary visual cortex and one deep-seated lesion including the right fornix (Tables 1 and 2 ). 
Seizure outcome
The mean follow-up was 16 months. Two patients (one treated with SRS and one with hfSRT) were completely seizure-free (ILAE 1) at the last available follow-up. One patient improved from ILAE 5 to ILAE 4. In the remaining three patients there was no apparent change in the seizure frequency after the stereotactic irradiation at the last available follow-up, in two patients after more than one year and in one patient after only 6 months.
The antiepileptic drugs could be stopped in one of the two patients, who became seizure-free. This patient is seizure-free without any medication since 5 months. All other patients were kept on their medications.
Complications, adverse events and safety of the procedures
There were no complications after both SRS or hfSRT. None of the patients developed any neurological impairment despite of the eloquent localization of the lesions.
MRI signal changes after irradiation therapy
In one patient (Pat. No. 1) the epileptogenic lesion shrank after hfSRT. In all other patients the lesions as well as the surrounding brain showed no neuro-imaging changes. In particularly, no edema was visible, which was the intention of the non ablative dose concept.
Discrepancy between the epileptogenic lesion and the epileptogenic zone
In all patients the stereotactic irradiation was performed highly selective on the putative epileptogenic lesion. However, in two cases the invasive diagnostic showed some epileptogenic activity beyond the MRI/MAP lesion (Pat. No. 3 and 4) . This implies that the epileptogenic zone possibly included larger areas than the visible MRI/MAP lesion itself. Of note, both patients continued to have seizures after the irradiation therapy.
Discussion
Treatment of drug resistant extratemporal epilepsies, arising from eloquent cortex areas, still represents a great challenge for both physicians and patients. Resective surgery of the epileptogenic lesion is known to be the gold standard for focal epilepsy. However, if the epileptogenic lesion involves eloquent cortex, it may be difficult to fulfill the main goal of epilepsy surgery -to reduce or stop disabling seizures, while preserving neurological function. The complex decision making process becomes even more difficult, when good seizure outcome can be achieved only at the expense of postoperative neurological impairments (''calculated deficit''). In order to overcome those difficulties, a number of minimal-invasive techniques have been recently introduced in the treatment of drug-resistant epilepsy due to eloquently localized lesions [8, 9, 23] . Those alternative possibilities include methods such as radiofrequency thermocoagulation, laser-induced thermal therapy, and focused ultrasound. Despite their minimal or noninvasive nature, all these treatment options share the same common feature -ablation of the lesion. Thus, the main epilepsy treatment effect is achieved by destruction of the epileptogenic lesion, which eventually could lead to neurological impairment as well. In contrast the use of low-dose stereotactic irradiation with SRS or hfSRT can represent a valuable and safe alternative, achieving relief of the seizure disorder without causing a neurological impairment. Here, we report our first experience of low-dose SRS and hfSRT for drug-resistant epilepsy caused by eloquent localized FCD-like lesions. Although there have been some studies, reporting radiosurgery for eloquently localized epileptogenic lesions, none of those focused particularly on the treatment of FCD. A recent study by McGonigal et al. in 2014 already reported Gamma Knife 1 radiosurgery for paracentral epileptogenic lesions [24] . In this study a comparatively high marginal dose (>24 Gy) was used. Four patients with focal epilepsy were treated with a mean follow-up of 49 months, during which 2/4 patients (50%) have benefited. The initial MRI findings were normal or atrophic in 2 cases and state after resection of astrocytoma or cortical dysplasia in the remaining 2 cases. Therefore, we think that these cases are difficult to compare with ours. This higher dose concept is exactly the approach which we did not intend in our case series. Barcia et al. (1994) have reported a lower dose radiosurgery concept with 10-20 Gy in 11 patients with focal epilepsy with a seizure free rate of 36%, in some cases sEEG was used but because of the limitations of the imaging technique at that time it remains unclear whether they have treated patients with a FCD [25] . A discussion and a comparison of low-dose and high-dose radiation concepts would of course be interesting, but the actual database from both directionsespecially concerning cortical dysplasia -is in our point of view not sufficient.
Outcome and effect of stereotactic irradiation
Two of six patients (33%) became completely seizure-free after SRS or hfSRT treatment. Our case series is focused on stereotactic irradiation for FCD-like lesions, it is difficult to compare the results reported here with other works. Nevertheless, this seizure free rate is comparable to the seizure free rate after SRS for hypothalamic hamartomas (40% seizure free) [12] . SRS for MTLE achieved better seizure outcome with seizure-free rates of 59%-76% [13, 26, 28] . However, the pathomechanisms of seizure development in MTLE or hypothalamic hamartomas differ immensely from those in FCD and this should be taken into consideration.
Interestingly, seizure freedom could be achieved although a low-dose irradiation was performed. This implies the presumption that it is not necessarily the destruction of the tissue but probably the neuromodulatory effect of irradiation, which could reduce or even stop the seizure activity. This idea has been supported and discussed by other groups as well [25, 27] .
No deficits despite eloquent area
One of the most important findings in this series was the absence of neurological deficits, despite the fact that all epileptogenic lesions were localized in eloquent cortex areas. The seizure outcome was not as good as those reported from resective surgery series for eloquent lesions, where seizure-free rates between 40% and 60% were reported [6, 29, 30] . However, in those series permanent neurological deficits occurred in approximately 20-30% of the cases, which was not the case in this patient cohort. As low-dose stereotactic irradiation does not preclude further non-or minimal invasive ablative techniques or even surgical resection, we think that irradiation of eloquent localized epileptogenic lesions could become a reasonable alternative to start with.
The epileptogenic lesion is not necessarily equal to the epileptogenic zone
Another well-known problem during the treatment of extratemporal epilepsy represents the exact determination of the epileptogenic zone, which sometimes differs from the localization of the epileptogenic lesion. In this series stereotactic irradiation was performed highly selective on the epileptogenic lesion. The series published by Rauch et al. [16] reported 11 patients, who were treated stereotactically with a LINAC. This series included 2 patients with extratemporal lesions, which were treated with a dedicated LINAC. However, this group used a different target volume definition with a safety margin of 1.5 cm, which was placed around the presumed epileptogenic focus and defined by magnetoencephalography. They used no additional invasive diagnostic like sEEG or grid implantation. In contrast, we have pursued a more in the strict sense stereotactical approach where no additional or just a very small safety margin of 1 mm was wrapped around the suspected epileptogenic focus.
However, in two patients, a possible second seizure generator could be detected beyond the targeted lesions. Of note, both patients failed to become seizure free. Whether a vaster irradiation field, including all sites of epileptogenic activity, could achieve a greater seizure benefit is an issue, which should be critically discussed and needs further investigation. Both patients are planned for an extensive epileptological re-evaluation.
Limitations
This study has a number of limitations. Due to the small sample size and short follow-up period the results should be cautiously interpreted, cannot be generalized and need to be confirmed by further studies. It is, however, important to stress that this case study was performed with the intention to report the feasibility and safety of SRS and hfSRT for extratemporal lesions localized in eloquent cortex areas. Another limitation is the lack of histological confirmation of the FCD. All lesions were however confirmed to be epileptogenic by established invasive or non invasive tools and all but two showed typical signs on the MRI, thus making them highly putative for FCD.
Conclusions
Our small case series suggest that low-dose radiosurgery or hypofractionated stereotactic radiotherapy could be a therapeutical option in refractory epilepsy due to epileptogenic lesions in highly eloquent areas. Larger studies are of course required to ascertain whether low-dose radiosurgery or hypofractionated stereotactic radiotherapy leads to sustained seizure-control in people with refractory epilepsy due to focal cortical dysplasia in the vicinity or within eloquent brain structures.
